AXA-042 - Axelia Oncology
https://oncologypro.esmo.org/meeting-resources/esmo-congress/axa-042-a-systemically-administered-tlr2-6-agonist-demonstrates-target-engagement-and-tlr-pathway-activation-in-patients-with-advanced-solid-tumors
 
B. Tran1; M. Millward2; C. Lemech3; S. Frentzas4; D. Day4; A. Latifi5; J. Desai6; P. Wabnitz7; P. Kearney8; A. Galkin9
 
Jul 27, 2023
 
Prev Next